Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medpace continues navigating a tricky biotech space fraught with funding challenges. MEDP stock is near another record high.

How Behind-The-Scenes Medpace Navigated A Biotech Slump To Hit A Record High

Catalyst Pharmaceuticals

Genmab - ADR

Inspire Medical Systems Inc

These leading biotech stocks have had a good quarter and some may have room to run, while for others it's time to ring the register. The post Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close appeared first on Investor's Business Daily.

Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close

Conagra Brands

Avis Budget Group

Liberty Oilfield Services

As brokers have more insight into stocks, one must follow rating upgrades before investing. We pick Conagra Brands (CAG), Medpace Holdings (MEDP), BP, Avis Budget Group (CAR) & Liberty Energy (LBRT), as these have seen rating upgrades.

5 Stocks With Upgraded Broker Ratings to Fight Macro Challenges

Axon Enterprise

Casey's General Stores

XPEL

There's good reason to expect these businesses to continue their histories of outperformance, regardless of market conditions.

These 4 Superb Growth Stocks Are Beating the Nasdaq Bear Market: Is It Too Late to Buy?

Medpace Holdings continues its period of growth with another set of strong quarterly numbers last period. In addition to the strong beat at the top and bottom lines, profitability trends continued to track higher.

Medpace: Buy Thesis Holds Spectacularly Amid Q3 Post-Earnings Drift

The clinical contract research organization is seeing an increase in new business.

Why Medpace Holdings Jumped 41.5% This Week

The clinical trial specialist is winning new business at an impressive clip.

Why Medpace Stock Soared Today

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q3 2022 Results Conference Call October 25, 2022 9:00 AM ET Company Participants Lauren Morris - IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants Dave Windley - Jefferies Sandy Draper - Guggenheim Partners Draper Max Smock - William Blair John Sourbeer - UBS Eric Coldwell - RW Baird Operator Good day, ladies and gentlemen, and welcome to the Medpace Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen only mode.

Medpace Holdings, Inc. (MEDP) Q3 2022 Earnings Call Transcript

Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. The post Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies appeared first on Investor's Business Daily.

Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies

Medpace (MEDP) delivered earnings and revenue surprises of 39.46% and 8.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2022.

Medpace Holdings, Inc. Reports Third Quarter 2022 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2022 financial results after the market close on Monday, October 24, 2022. The Company will host a conference call the following morning, Tuesday, October 25, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo

Medpace Holdings, Inc. to Report Third Quarter 2022 Financial Results on October 24, 2022

Seagen

Biogen

BioMarin Pharmaceutical

Bristol-Myers

Merck

Thermo Fisher Scientific

Zimmer Biomet Hlds

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

These eight health-care stocks can keep you invested in the market with less worry

Doximity

Veeva Systems

These healthcare stocks could help you retire early, offering impressive margins and promising growth potential.

Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade

Medpace delivered a robust set of Q2 earnings with upsides on revenue and operating income. The company printed above-average FCF conversion and continues to deliver on long-term capital management trends.

Medpace: On Pace After Q1 FY22 Earnings Momentum

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2022 Earnings Conference Call July 26, 2022 9:00 AM ET Company Participants Lauren Morris - Director of Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants Dave Windley - Jefferies Christine Rains - William Blair Sandy Draper - Guggenheim Partners Paul Knight - KeyBanc Eric Coldwell - Robert W. Baird David Windley - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Medpace Second Quarter 2022 Earnings Conference Call.

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2022 Results - Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 8.96% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q2 Earnings and Revenues Top Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Results Revenue for the three months ended June 30, 2022 increased 26.2% to $351.2 million, compared to $278.3 million for the comparable prior-year period. On a constant currency organic basis, revenue for the second quarter of 2022 increased 27.7% compared to the second quarter of 2021. Backlog as of June 30,

Medpace Holdings, Inc. Reports Second Quarter 2022 Results

Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Medpace (MEDP) Ahead of Earnings?

Crane Company

Hess

Zions Bancorp

Five companies will report second-quarter 2022 earnings results next week. These are: EQT, MEDP, CR, HES and ZION.

5 Stocks to Buy Ahead of Q2 Earnings Results Next Week

A Relative Strength Rating upgrade for Medpace shows improving technical performance. Will it continue?

Stocks With Rising Relative Strength: Medpace

Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth

Delek US Hlds

Texas Pacific Land Trust

Invest in stocks like Medpace (MEDP), Texas Pacific Land (TPL) & Delek US Holdings (DK) at the moment for solid earnings growth.

3 Top Stocks to Bet on for Superb Earnings Growth

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2022 financial results after the market close on Monday, July 25, 2022. The Company will host a conference call the following morning, Tuesday, July 26, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10

Medpace Holdings, Inc. to Report Second Quarter 2022 Financial Results on July 25, 2022

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for Medpace Holdings Stock (MEDP)